Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel A Wells

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Surgery|January 20, 2005
Hereditary medullary thyroid carcinoma in patients greater than 50 years oldFrank J Quayle, Ronald Benveniste, Mary K DeBenedetti, et al.
The New England Journal of Medicine|September 16, 2005
Prophylactic thyroidectomy in multiple endocrine neoplasia type 2AMichael A Skinner, Jeffrey A Moley, William G Dilley, et al.
Diagnostic Cytopathology|May 15, 2008
Training, credentialing and re-credentialing for the performance of a thyroid FNA: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science ConferenceBritt-Marie E Ljung, Jill Langer, Ernest L Mazzaferri, et al.
The Journal of Clinical Endocrinology and Metabolism|November 20, 2013
The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutationsChan Kwon Jung, Mark P Little, Jay H Lubin, et al.
Annals of Surgery|September 15, 2015
Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2Jeffrey F Moley, Michael Skinner, William E Gillanders, et al.
Journal of the American College of Surgeons|September 30, 2004
A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology GroupLisa A Newman, Thelma Hurd, Marilyn Leitch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerSamuel A Wells, Jessica E Gosnell, Robert F Gagel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2012
Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastasesAnna Tamburrino, Alfredo A Molinolo, Paolo Salerno, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2002
Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st centuryJohn P Bilezikian, John T Potts, Ghada El-Hajj Fuleihan, et al.
The Journal of Clinical Endocrinology and Metabolism|December 6, 2002
Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st centuryJohn P Bilezikian, John T Potts, Ghada El-Hajj Fuleihan, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Surgery|January 20, 2005
Hereditary medullary thyroid carcinoma in patients greater than 50 years oldFrank J Quayle, Ronald Benveniste, Mary K DeBenedetti, et al.
The New England Journal of Medicine|September 16, 2005
Prophylactic thyroidectomy in multiple endocrine neoplasia type 2AMichael A Skinner, Jeffrey A Moley, William G Dilley, et al.
Diagnostic Cytopathology|May 15, 2008
Training, credentialing and re-credentialing for the performance of a thyroid FNA: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science ConferenceBritt-Marie E Ljung, Jill Langer, Ernest L Mazzaferri, et al.
The Journal of Clinical Endocrinology and Metabolism|November 20, 2013
The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutationsChan Kwon Jung, Mark P Little, Jay H Lubin, et al.
Annals of Surgery|September 15, 2015
Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2Jeffrey F Moley, Michael Skinner, William E Gillanders, et al.
Journal of the American College of Surgeons|September 30, 2004
A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology GroupLisa A Newman, Thelma Hurd, Marilyn Leitch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2010
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancerSamuel A Wells, Jessica E Gosnell, Robert F Gagel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2012
Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastasesAnna Tamburrino, Alfredo A Molinolo, Paolo Salerno, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 5, 2002
Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st centuryJohn P Bilezikian, John T Potts, Ghada El-Hajj Fuleihan, et al.
The Journal of Clinical Endocrinology and Metabolism|December 6, 2002
Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st centuryJohn P Bilezikian, John T Potts, Ghada El-Hajj Fuleihan, et al.
Pageof 5